Bracco touts contrast study results

Italian contrast firm Bracco said that results from the Patients with Renal Impairment and Diabetes undergoing CT (PREDICT) trial show no statistically significant difference between its Isovue-370 low-osmolar CT contrast agent and the Visipaque 320 isomolar agent (GE Healthcare, Chalfont St. Giles, U.K.) in the rate of contrast-induced nephropathy in high-risk patients undergoing CT studies.

The results were recently published in the American Journal of Roentgenology, according to Bracco of Milan.

Related Reading

Bracco completes E-Z-EM acquisition, April 2, 2008

Bracco to acquire E-Z-EM, October 30, 2007

Bracco, ImaRx sign licensing pact, July 4, 2007

Copyright © 2008

Page 1 of 1235
Next Page